Share this article

AstraZeneca has posted a profit after tax of $1.37bn for the third quarter (Q3) of 2023, compared with $1.64bn in the same quarter of the previous year, indicating a decline of 16% on an actual basis.

For the quarter ended 30 September 2023, the company saw a 17% rise in gross profit to $9.39bn from $8.0bn in Q3 2022.

The earnings per share (EPS) on a reported basis was $0.89 compared with $1.06 in the third quarter of 2022, signifying a 16% drop. 

The company’s earnings before interest, taxes, depreciation, and amortisation rose by 25% to $3.23bn from 2.57 in Q3 2022.

Revenue was $11.49bn versus $10.98bn in the third quarter of 2022, up 5% on an actual basis.  

In the oncology therapy area, the company’s revenues stood at $4.66bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Revenues were $2.68bn in cardiovascular, renal and metabolism areas, $1.54bn in respiratory and immunology areas, $312m in vaccines and immune therapies, and $1.97bn in rare diseases.

Product sales were reported at $11.01bn from $10.59bn in Q3 2022, indicating a growth of 4%.

AstraZeneca CEO Pascal Soriot stated: “Our company continued its strong growth trajectory in the third quarter with total revenue from our non‑Covid-19 medicines up 13% compared to last year. 

“Given the momentum in the year to date, we have increased our full-year guidance for total revenue excluding Covid medicines, as well as for core EPS.”

In early November 2023, the company entered a partnership with Eccogene for ECC5004, a small molecule GLP-1 agonist.